Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.52 |
| ▸ | ITGAV | P06756 | 14/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153763 | 0.83 | PDE10A (0.54) | PDE10AITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL8343868 | 0.78 | PDE10A (0.50) | PDE10AITGAVITGB3ITGB6ITGB5 | |
| SCHEMBL21767449 | 0.76 | PDE10A (0.44) | PDE10AITGAVITGB6 | |
| SCHEMBL21767452 | 0.76 | PDE10A (0.44) | PDE10AITGAVITGB6 | |
| SCHEMBL19514916 | 0.75 | ITGAV (0.45) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL21856499 | 0.74 | PDE10A (0.42) | PDE10AITGAVITGB3ITGB6 | |
| SCHEMBL21856498 | 0.74 | PDE10A (0.42) | PDE10AITGAVITGB3ITGB6 | |
| SCHEMBL19393940 | 0.74 | ITGAV (0.46) | PDE10AITGAVITGB3ITGB6 | |
| SCHEMBL4716711 | 0.72 | ITGAV (0.55) | ITGAVITGB3ITGB6ITGB5ITGA2B | |
| SCHEMBL4253493 | 0.72 | PDE10A (0.45) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252162-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-07-25 | — | — | EP | disclosed |
| US-6472403-B2 | IMIDAZOLIDIN-2-ONE DERIVATIVES; INHIBITING BONE RESORPTION, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020037889-A1 | Alpha V integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037889-A1 | Alpha V integrin receptor antagonists | ITGAV, ITGB3, ITGA5 | PDE10A 3574/4885ITGAV 1/4885ITGB3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.